Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 12/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893587 | 0.87 | NR1H3 (0.56) | NR1H3NR1H2SMN1; SMN2RORCRORA | |
| SCHEMBL4427665 | 0.84 | NR1H2 (0.55) | NR1H3NR1H2SMN1; SMN2RORCMLYCD | |
| SCHEMBL4597093 | 0.83 | HSD11B1 (0.44) | NR1H3NR1H2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4881350 | 0.82 | NR1H2 (0.54) | NR1H3NR1H2SMN1; SMN2RORCMLYCD | |
| SCHEMBL2077709 | 0.81 | SMN1; SMN2 (0.51) | NR1H3NR1H2SMN1; SMN2RORCRORA | |
| SCHEMBL13798571 | 0.80 | MAPT (0.40) | NR1H3NR1H2SMN1; SMN2RORC | |
| SCHEMBL10721177 | 0.80 | ESR1 (0.45) | NR1H3NR1H2SMN1; SMN2 | |
| SCHEMBL1797711 | 0.79 | KIF11 (0.52) | SMN1; SMN2 | |
| SCHEMBL12403856 | 0.78 | SMN1; SMN2 (0.58) | NR1H3NR1H2SMN1; SMN2RORCRORA | |
| Iodide SCHEMBL29229874 | 0.78 | KIF11 (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980353-B | ROR gamma modulators | 领先制药控股公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-3077372-B1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2019-02-06 | — | — | EP | disclosed |
| US-20180258133-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | ORPHAGEN PHARMACEUTICALS INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | ORPHAGEN PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | ORPHAGEN PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9738600-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-9657053-B2 | Modulators of retinoid-related orphan receptor gamma | Orphagen Pharmaceuticals (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657053-B2 | Modulators of retinoid-related orphan receptor gamma | Orphagen Pharmaceuticals (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-10-20 | — | — | US | disclosed |
| US-20100004297-A1 | NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES | DEHMLOW HENRIETTA | 2010-01-07 | — | — | US | disclosed |
| US-7608721-B2 | Hexafluoroisopropanol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080096937-A1 | Novel hexafluoroisopropanol derivatives | DEHMLOW HENRIETTA | 2008-04-24 | — | — | US | disclosed |
| US-20070213377-A1 | Novel hexafluoroisopropanol derivatives | DEHMLOW HENRIETTA | 2007-09-13 | — | — | US | disclosed |
| US-7259178-B2 | Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1972897-A | Novel hexafluoroisopropanol derivative | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | disclosed |
| EP-1763502-A1 | NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| US-20060004068-A1 | Novel hexafluoroisopropanol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | US | disclosed |
| WO-2006000323-A1 | NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-4218448-A | Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258133-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RORC, RORB, RORA | NR1H3 12/4885NR1H2 11/4885SMN1; SMN2 3335/4885 |
| US-20070213377-A1 | Novel hexafluoroisopropanol derivatives | NR1H3, NR1H2, NR1I2 | NR1H3 1/4885NR1H2 2/4885SMN1; SMN2 4516/4885 |
| US-20100004297-A1 | NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES | NR1H3, NR1H2, NR1I2 | NR1H3 1/4885NR1H2 2/4885SMN1; SMN2 4516/4885 |
| US-20080096937-A1 | Novel hexafluoroisopropanol derivatives | NR1H3, NR1H2, NR1I2 | NR1H3 1/4885NR1H2 2/4885SMN1; SMN2 4516/4885 |
| US-20160304448-A1 | ROR GAMMA (RORy) MODULATORS | RORC, RORA, RORB | NR1H3 14/4885NR1H2 18/4885SMN1; SMN2 3833/4885 |
| US-20060004068-A1 | Novel hexafluoroisopropanol derivatives | NR1H3, NR1H2, NR1I2 | NR1H3 1/4885NR1H2 2/4885SMN1; SMN2 4516/4885 |
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RORC, RORB, RORA | NR1H3 12/4885NR1H2 11/4885SMN1; SMN2 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.